{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-214871","form_type":"8-K","ticker":"AVIR","cik":"0001593899","company_name":"Atea Pharmaceuticals, Inc.","filed_at":"2022-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.299752+00:00","generated_at":"2026-06-24T02:48:54.541234+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Atea Pharma Q2 net loss $31.3M; bemnifosbuvir enters late-stage COVID-19 trial","bullets":["Net loss of $31.3M ($0.38 diluted loss per share) vs net income of $1.5M in Q2 2021; no collaboration revenue.","Cash and equivalents $684.5M at June 30, 2022, down from $764.4M at Dec 31, 2021.","Bemnifosbuvir to advance to global late-stage trial for COVID-19 in Q4 2022; primary endpoint hospitalization/death in high-risk patients.","MORNINGSKY Phase 3 missed primary symptom alleviation endpoint but showed 71% reduction in hospitalization (exploratory p=0.047).","AT-752 for dengue and HCV combo trial advancing; initial results expected Q4 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-214871","json":"https://secwatch.observer/filing/0001193125-22-214871.json","markdown":"https://secwatch.observer/filing/0001193125-22-214871.md","text":"https://secwatch.observer/filing/0001193125-22-214871.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1593899/000119312522214871/0001193125-22-214871-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1593899/000119312522214871/d356253d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:48:54.541234+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}